吉利德科学公司(Gilead Sciences)周二表示该公司生产的用于预防艾滋病感染的一年两次注射剂已获得欧盟执委会的

智通财经
Aug 26
吉利德科学公司(Gilead Sciences)周二表示该公司生产的用于预防艾滋病感染的一年两次注射剂已获得欧盟执委会的上市许可。该药学名来那卡帕韦(lenacapavir)将以Yeytuo的品牌在欧洲销售。该药已于 6 月获得美国监管机构的批准在美国市场上以 Yeztugo 的名称销售。欧盟执委会的批准适用于欧盟27个成员国以及挪威、冰岛和列支敦士登。在向患者提供这种药物之前吉利德公司需要与各国的卫生系统确定定价和报销条款。分析师预计到 2029 年这种药物的年销售额将超过 40 亿美元。欧盟执委会批准将这种药物用于暴露前预防(PrEP)以降低感染致命病毒风险较高的成人和青少年通过性途径感染艾滋病毒的风险。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10